Future heart events such as heart attacks, cardiovascular diseases and strokes can be averted with high doses of statin drugs. But a study done by researchers shows a number of patients with heart diseases risk were not taking the recommended statin drugs. Researchers have done follow up studies on 30,000 Medicare heart attack patients, aged between 66 to 75 years, who received "high-intensity" statin drugs prescription during their hospitalization with the heart attack or stroke. When researchers did follow up studies after two years, researchers found
As statin drugs prevent future risks associated with stroke and heart attacks, heart patients should continue using them with drug dosage prescribed by the physician. Lead author of the study was Professor Robert Rosenson, at the Icahn School of Medicine, Mount Sinai, New York City and the study findings were published April 19, 2017, in the JAMA Cardiology.
Canagliflozin (marketed as Invokana) is a SGLT2 inhibitor drug for the treatment of type 2 diabetes (T2D) patients. In an ongoing research being conducted by the researchers from the University of Alabama shows a reduction in function of fat or adipose tissue with canagliflozin when compared with glimepiride treatment. The reduction in fat or adipose tissue function is independent of weight loss. The reduction in adipose tissue causes a big impact on changes in energy balance and body metabolism.
Researchers are conducting CANVAS study between two groups of type 2 diabetes (T2D) adults. One group of type 2 diabetes (T2D) individuals are being treated daily with 300 mg of canagliflozin for 52 weeks duration. Similarly, another group of type 2 diabetes (T2D) individuals are being treated with glimepiride (marketed as Amaryl). They observed and analyzed samples for changes in body weight, HbA1c levels along with fat or adipose tissue function. At the end of 52 weeks, researchers observed following conditions in canagliflozin (marketed as Invokana) group when compared with glimepiride group.
Lead author of the study was Timothy W Garvey, MD and the study findings were presented at the American Association of Clinical Endocrinologists (AACE), 26th Annual Scientific and Clinical Congress 2017, held at Austin, Texas, United States. After completion of current CANVAS study, findings on cardiovascular outcomes with canagliflozin will be declared.
Glimepiride : Some type 2 diabetes (T2D) patients cannot reduce blood sugar levels with diet and physical exercise. Glimepiride drug, a sulfonylurea antidiabetic medicine is intended to reduce blood sugar or glucose levels in those patients by triggering the pancreas to release insulin.
Adipose tissue : Adipose tissue function is storing calories in the form of fat under the skin, around internal organs, breast tissue and bone marrow. This tissue insulates body too. But its function will be weakened in overweight or obese people, a risk factor to type 2 diabetes (T2D).
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.